AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28453969 — intervention group
Group type: EXPERIMENTAL
Intervention: usual care plus cognitive task procedure (visuospatial task using 'Tetris' for 15 minutes within six hours after ECS)
Number of subjects: 56
Study 28453969 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 56
Study 26580673 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare™ weaning
Number of subjects: 70
Study 26580673 — intervention group
Group type: COMPARATOR
Intervention: Respiratory physiotherapy-driven weaning
Number of subjects: 70
Study 24238397 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders (daily messages reminding them of aspects regarding taking their medication)
Number of subjects: 1198
Study 24238397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 1198
Study 21068341 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 4128
Study 18307223 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal (AS)
Number of subjects: 450
Study 18307223 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose (SC)
Number of subjects: 450
Study 18307223 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 450
Study 16935174 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U of botulinum toxin A (BTX‐A)
Number of subjects: 30
Study 16935174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U of botulinum toxin A (BTX‐A)
Number of subjects: 30
Study 16935174 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 30
Study 12951885 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose ingestion during oral glucose tolerance test
Number of subjects: 50
Study 9500558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 60
Study 7632121 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple‐family group treatment
Number of subjects: 172
Study 7632121 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational single‐family treatment
Number of subjects: 172
Study 7632121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 172
Study 2565687 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine alone (1.25 and 2.5 mg twice daily)
Number of subjects: 212
Study 2565687 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine with guanfacine (1 mg daily after 8 weeks)
Number of subjects: 212
Study 2565687 — intervention group
Group type: COMPARATOR
Intervention: Isradipine alone
Number of subjects: 212
Study 2565687 — intervention group
Group type: COMPARATOR
Intervention: Isradipine with guanfacine
Number of subjects: 212
Study 836732 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured questionnaire record
Number of subjects: 278
Study 836732 — intervention group
Group type: COMPARATOR
Intervention: Standard case notes
Number of subjects: 278
Study 836732 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical operation as a result of investigation
Number of subjects: 278
Study 31432381 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit intervention
Number of subjects: 322
Study 28918754 — intervention group
Group type: EXPERIMENTAL
Intervention: MALS diagnosis based on hemophagocytic syndrome score and/or hepatobiliary dysfunction and disseminated intravascular coagulation
Number of subjects: 5121
Study 28918754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin level above 4420 ng/ml
Number of subjects: 5121
Study 28918754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measurements on day 3
Number of subjects: 5121
Study 25038558 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of diabetes management protocols using certified diabetes educators (CDEs)
Number of subjects: 15
Study 25038558 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study 21940989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 729
Study 21940989 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 729
Study 19116322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59)
Number of subjects: 120
Study 19116322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 120
Study 17574821 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 17574821 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30
Study 17574821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study 15342847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal psychological distress at 40 weeks gestation
Number of subjects: 869
Study 15342847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cigarette smoking during pregnancy
Number of subjects: 869
Study 15342847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 869
Study 15342847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 869
Study 11161541 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (parenteral nutrition without lipids)
Number of subjects: 10
Study 11161541 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (parenteral nutrition with lipids)
Number of subjects: 10
Study 9550543 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective β1‐adrenoceptor antagonist atenolol (0.062 mg · kg‐1 body weight) administered immediately after exercise (EXAT)
Number of subjects: 7
Study 9550543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β‐adrenoceptor antagonist propranolol (0.15 mg · kg‐1 body weight) administered after exercise (EXPRO)
Number of subjects: 7
Study 9550543 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection instead of β‐antagonist (EX)
Number of subjects: 7
Study 9550543 — intervention group
Group type: COMPARATOR
Intervention: Control with selective β1‐adrenoceptor antagonist atenolol (REAT)
Number of subjects: 7
Study 9550543 — intervention group
Group type: COMPARATOR
Intervention: Control with nonselective β‐adrenoceptor antagonist propranolol (REPRO)
Number of subjects: 7
Study 9550543 — intervention group
Group type: COMPARATOR
Intervention: Control with saline (RE)
Number of subjects: 7
Study 7917532 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (C)
Number of subjects: 57
Study 7917532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2679236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) treatment group
Number of subjects: 0
Study 2679236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2679236 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC treatment group with impaired LV function
Number of subjects: 0
Study 2679236 — intervention group
Group type: COMPARATOR
Intervention: Control group with impaired LV function
Number of subjects: 0
Study 2679236 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC treatment group
Number of subjects: 0
Study 630909 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg fenfluramine plus a 1600 calorie diet
Number of subjects: 15
Study 630909 — intervention group
Group type: COMPARATOR
Intervention: placebo plus a 1600 calorie diet
Number of subjects: 15
Study 630909 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg fenfluramine
Number of subjects: 15
Study 31455398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid wrist splint
Number of subjects: 112
Study 31455398 — intervention group
Group type: COMPARATOR
Intervention: Soft wrist bandage (placebo)
Number of subjects: 112
Study 27225284 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual components training (10 sessions including components such as image of God, relationship with God, Tawwakul, searching for meaning during difficulties and pain)
Number of subjects: 40
Study 27225284 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 40
Study 25257238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild- to moderate-intensity aerobic exercise training programme for six weeks during radiotherapy
Number of subjects: 58
Study 25257238 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group without special exercise intervention
Number of subjects: 58
Study 23509160 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox
Number of subjects: 319
Study 23509160 — intervention group
Group type: COMPARATOR
Intervention: Airox
Number of subjects: 319
Study 23509160 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (facemask tolerant subgroup)
Number of subjects: 319
Study 23509160 — intervention group
Group type: COMPARATOR
Intervention: Airox (facemask tolerant subgroup)
Number of subjects: 319
Study 23509160 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (nasal cannula subgroup)
Number of subjects: 319
Study 23509160 — intervention group
Group type: COMPARATOR
Intervention: Airox (nasal cannula subgroup)
Number of subjects: 319
Study 23509160 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (subgroup started on CPAP)
Number of subjects: 319
Study 23509160 — intervention group
Group type: COMPARATOR
Intervention: Airox (subgroup started on CPAP)
Number of subjects: 319
Study 20672256 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention (12 sessions of 30 minutes each, twice a week for 6 weeks)
Number of subjects: 100
Study 20672256 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 100
Study 19769477 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (listening to preselected soft music for 15 minutes)
Number of subjects: 114
Study 19769477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma group (inhaling Citrus bergamia essential oil vapor for 15 minutes)
Number of subjects: 114
Study 19769477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined music and aroma group
Number of subjects: 114
Study 19769477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 114
Study 16477553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-free intervention at Caen Hospital
Number of subjects: 1093
Study 16477553 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (three university hospitals)
Number of subjects: 1093
Study 16784179 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg per day)
Number of subjects: 18
Study 16784179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14555256 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping program (25 jumps/day from a 45‐cm box, 5 days/week for 12 weeks)
Number of subjects: 54
Study 14555256 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping program
Number of subjects: 54
Study 11456252 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.50%
Number of subjects: 40
Study 11456252 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol HCL 0.50%
Number of subjects: 40
Study 8953683 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem 500 mg every 8 h
Number of subjects: 118
Study 8953683 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg every 6 h
Number of subjects: 118
Study 2044986 — intervention group
Group type: EXPERIMENTAL
Intervention: Money management service (n = 40)
Number of subjects: 63
Study 2044986 — intervention group
Group type: COMPARATOR
Intervention: Customary screening by the Office of the Public Guardian or Adult Protective Services (n = 23)
Number of subjects: 63
Study 6793920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate 1.8 g
Number of subjects: 61
Study 6793920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31415482 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (narrated, educational presentation by computer)
Number of subjects: 48
Study 31415482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 48
Study 27398685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pull specific (HPS)
Number of subjects: 9
Study 27398685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle+HPS
Number of subjects: 9
Study 27398685 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV+HPS
Number of subjects: 9
Study 27398685 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 25902814 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly menstrual migraine (MM)
Number of subjects: 1697
Study 25902814 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrually-associated migraine (MAM)
Number of subjects: 1697
Study 25902814 — intervention group
Group type: COMPARATOR
Intervention: Menstrually-unrelated migraine (MUM)
Number of subjects: 1697
Study 23425564 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10mg/day) + Exemestane (25mg/day)
Number of subjects: 724
Study 23425564 — intervention group
Group type: COMPARATOR
Intervention: Exemestane only (placebo)
Number of subjects: 724
Study 21051765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 40
Study 21051765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 20028263 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 59
Study 20028263 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 0.25%
Number of subjects: 59
Study 17465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 95
Study 17465257 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alternating with paclitaxel/cisplatin
Number of subjects: 95
Study 14997127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 100
Study 14997127 — intervention group
Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 100
Study 11528536 — intervention group
Group type: EXPERIMENTAL
Intervention: General characteristics and content of neuropsychological reports
Number of subjects: 414
Study 9292756 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 1 (121g carbohydrate, 16g protein, 48g fat)
Number of subjects: 8
Study 9292756 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 2 (70g carbohydrate, 16g protein, 70g fat)
Number of subjects: 8
Study 9292756 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 3 (50g carbohydrate, 14g protein, 80g fat)
Number of subjects: 8
Study 9292756 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 4 (0g carbohydrate, 0g protein, 108g fat)
Number of subjects: 8
Study 8084248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein load in Group I (reflux patients)
Number of subjects: 24
Study 8084248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein load in Group II (urinary infection patients)
Number of subjects: 24
Study 8084248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein load in Group III (healthy controls)
Number of subjects: 24
Study 8084248 — intervention group
Group type: EXPERIMENTAL
Intervention: Control period in Group I (reflux patients)
Number of subjects: 24
Study 8084248 — intervention group
Group type: COMPARATOR
Intervention: Control period in Group II (urinary infection patients)
Number of subjects: 24
Study 8084248 — intervention group
Group type: COMPARATOR
Intervention: Control period in Group III (healthy controls)
Number of subjects: 24
Study 3318465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villi sampling
Number of subjects: 61
Study 3318465 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 61
Study 31924473 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine
Number of subjects: 0
Study 31924473 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block
Number of subjects: 0
Study 30303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians provided with vignettes of hypothetical patients
Number of subjects: 1223
Study 30303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors unrelated to severity of illness (ICU bed availability mentioned vs. unmentioned)
Number of subjects: 1223
Study 30303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors unrelated to severity of illness (family presence vs. unmentioned)
Number of subjects: 1223
Study 30303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 1223
Study 27882820 — intervention group
Group type: EXPERIMENTAL
Intervention: AXL1717 (AXL) 300 or 400 mg daily BID
Number of subjects: 99
Study 27882820 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (DCT) 75 mg/m2 in three-week cycles
Number of subjects: 99
Study 27882820 — intervention group
Group type: EXPERIMENTAL
Intervention: AXL1717 (AXL)
Number of subjects: 99
Study 27882820 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (DCT)
Number of subjects: 99
Study 26037479 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive device with visual and acoustic instructions for ALS workflow measures
Number of subjects: 42
Study 26037479 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR equipment
Number of subjects: 42
Study 24386809 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) via nasal cannula, administered continuously every day for one year.
Number of subjects: 96
Study 21481871 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Number of subjects: 40
Study 21481871 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 40
Study 21481871 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET)
Number of subjects: 40
Study 19190265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (65 energy-% Fat)
Number of subjects: 12
Study 19190265 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (65 energy-% CHO)
Number of subjects: 12
Study 19190265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1 h of one-legged knee extensor exercise)
Number of subjects: 12
Study 16923003 — intervention group
Group type: EXPERIMENTAL
Intervention: VRR algorithm (INSIGNIA pacemakers)
Number of subjects: 58
Study 16923003 — intervention group
Group type: COMPARATOR
Intervention: Fixed rate stimulation at 60 ppm (Control)
Number of subjects: 58
Study 15532380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (24.4 +/- 2.0 mg/day) + Fosinopril (2.5-40 mg/day)
Number of subjects: 50
Study 15532380 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (44.1 +/- 5.1 mg/day) + Fosinopril (2.5-40 mg/day)
Number of subjects: 50
Study 12036674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurements by endocrinologist and ophthalmologist using Krahn exophthalmometer
Number of subjects: 0
Study 12036674 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT) scans
Number of subjects: 0
Study 12036674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurements by different clinicians
Number of subjects: 0
Study 9791321 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fitness walking program
Number of subjects: 47
Study 9791321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 8608070 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 66
Study 8608070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 66
Study 2670719 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate (antacid poor in aluminum)
Number of subjects: 19
Study 2670719 — intervention group
Group type: COMPARATOR
Intervention: Compound M 70 (antacid rich in aluminum)
Number of subjects: 19
Study 791444 — intervention group
Group type: EXPERIMENTAL
Intervention: Depilatory cream
Number of subjects: 0
Study 791444 — intervention group
Group type: COMPARATOR
Intervention: Routine shaving
Number of subjects: 0
Study 31526767 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa medication (on medication)
Number of subjects: 23
Study 31526767 — intervention group
Group type: COMPARATOR
Intervention: Training off levodopa medication (off medication)
Number of subjects: 23
Study 31172719 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab Q4W
Number of subjects: 122
Study 31172719 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab Q8W
Number of subjects: 122
Study 31172719 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 122
Study 26626800 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40-60 mg/m2 twice daily) for 2 weeks, followed by S-1 and oxaliplatin (100 mg/m2) for 8 cycles
Number of subjects: 63
Study 25223844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), manualized exposure-based
Number of subjects: 231
Study 25223844 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) add-on study
Number of subjects: 231
Study 23732258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bascom cleft lift
Number of subjects: 122
Study 23732258 — intervention group
Group type: COMPARATOR
Intervention: Limberg flap
Number of subjects: 122
Study 21831418 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel doublet chemotherapy (4 cycles: 3 weeks on treatment, 1 week off; carboplatin on day 1, paclitaxel on days 1, 8, and 15)
Number of subjects: 451
Study 21831418 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine or gemcitabine monotherapy (5 cycles: 2 weeks on treatment, 1 week off)
Number of subjects: 451
Study 21831418 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy
Number of subjects: 451
Study 19389795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy followed by 12 cycles of modified FOLFOX6 (mFOLFOX6) regimen
Number of subjects: 300
Study 19389795 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 300
Study 16713809 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loaded (IL) group (n=24)
Number of subjects: 48
Study 16713809 — intervention group
Group type: COMPARATOR
Intervention: Immediate Provisionalized (IP) group (n=24)
Number of subjects: 48